Get started
Author

Brian W. Ogilvie

Observed names: Brian Ogilvie, Brian W Ogilvie
ORCID: 0000-0001-7581-893X
Observed ORCID: 0000-0001-7581-893X
OpenAlex ID: A5063752035
Glucuronidation Converts Gemfibrozil to a Potent, Metabolism-dependent Inhibitor of Cyp2c8: Implications for Drug-drug Interactions
2005 · Brian W. Ogilvie, Donglu Zhang, et al. · Drug Metabolism and Disposition · 331
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters
2015 · Lydia M. M Vermeer, Caleb D Isringhausen, et al. · Drug Metabolism and Disposition · 125
The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel
2011 · Brian W. Ogilvie, Phyllis Yerino, et al. · Drug Metabolism and Disposition · 121
Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments
2011 · Takao Watanabe, Hiroyuki Kusuhara, et al. · Drug Metabolism and Disposition · 99
System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase (UGT) Enzymes: Human Hepatocytes versus Liver Microsomes versus Recombinant Enzymes
2010 · Andrew Parkinson, Faraz Kazmi, et al. · Drug Metabolism and Pharmacokinetics · 87
The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments
2015 · Lois J. Haupt, Faraz Kazmi, et al. · Drug Metabolism and Disposition · 71
An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes
2011 · Andrew Parkinson, Faraz Kazmi, et al. · Drug Metabolism and Disposition · 70
In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran
2009 · Brandy L. Paris, Brian W. Ogilvie, et al. · Drug Metabolism and Disposition · 70
Construction of Triple-Transfected Cells [Organic Anion-Transporting Polypeptide (OATP) 1B1/Multidrug Resistance-Associated Protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for Analysis of the Sinusoidal Function of MRP3 and MRP4
2009 · Masakazu Hirouchi, Hiroyuki Kusuhara, et al. · Drug Metabolism and Disposition · 46
Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416
2005 · Christine Ye, David Sweeny, et al. · Toxicology in Vitro · 43
In Vitro Approaches for Studying the Inhibition of Drug-Metabolizing Enzymes and Identifying the Drug-Metabolizing Enzymes Responsible for the Metabolism of Drugs (Reaction Phenotyping) with Emphasis on Cytochrome P450
2019 · Brian W. Ogilvie, Etsuko Usuki, et al. · CRC Press eBooks · 33
In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
2022 · Parthena Martin, Maciej Czerwiński, et al. · Pharmacology Research & Perspectives · 25
Clinical assessment of drug–drug interactions of tasimelteon, a novel dual melatonin receptor agonist
2015 · Brian W. Ogilvie, Rosarelis Torres, et al. · The Journal of Clinical Pharmacology · 25
PDF
An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides
2018 · Faraz Kazmi, Phyllis Yerino, et al. · Drug Metabolism and Disposition · 22
In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions
2022 · Parthena Martin, Maciej Czerwiński, et al. · Pharmacology Research & Perspectives · 21
PDF
Biotransformation of the Anti-Angiogenic Compound SU5416
2000 · Lida Antonian, Hongbing Zhang, et al. · Drug Metabolism and Disposition · 21
An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes
2009 · Alaa-Eldin F. Nassar, Ivan King, et al. · Drug Metabolism and Disposition · 19
On the Mechanism of Hepatocarcinogenesis of Benzodiazepines: Evidence that Diazepam and Oxazepam are CYP2B Inducers in Rats, and both CYP2B and CYP4A Inducers in Mice
2006 · Andrew Parkinson, Neda Leonard, et al. · Drug Metabolism Reviews · 19
Human Biotransformation
2010 · Andrew Parkinson, Brian W. Ogilvie, et al. · Wiley eBooks · 15
Use of Enzyme Inhibitors to Evaluate the Conversion Pathways of Ester and Amide Prodrugs: A Case Study Example with the Prodrug Ceftobiprole Medocaril
2011 · Gary Eichenbaum, Jennifer Skibbe, et al. · Journal of Pharmaceutical Sciences · 8
Effects of monocyte chemoattractant protein‐1, macrophage inflammatory protein‐1α, and interferon‐α2a on P450 enzymes in human hepatocytes in vitro
2019 · Maciej Czerwiński, Krystal Gilligan, et al. · Pharmacology Research & Perspectives · 6
PDF
Drugs as victims and perpetrators and the pharmacokinetic concept of maximum exposure
2014 · Brian W. Ogilvie, Andrew Parkinson · Wiley eBooks · 4
The in vitro evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors (ritonavir, clarithromycin and itraconazole) as inhibitors of non-CYP enzymes
2017 · David B. Buckley, Brian W. Ogilvie, et al. · Drug Metabolism and Pharmacokinetics · 2
An in Vitro Investigation Into the Mechanism of the Clinically Relevant Drug-drug Interaction Between Omeprazole or Esomeprazole and Clopidogrel
2015 · Brian W. Ogilvie · KU ScholarWorks (The University of Kansas) · 2
PDF
Microsomal cytochrome P450 enzyme activities in nonalcoholic steatohepatitis livers
2019 · Maciej Czerwinski, Brian Oberheide, et al. · Drug Metabolism and Pharmacokinetics · 1
Works count: 28
Citation count: 1,286
H-index: 18
I10-index: 19
Year
Topic
Type